The Open Payments database at the Centers for Medicare & Medicaid Services continues to shine a bright light on the association between industry payments to physicians by drug and medical device companies and prescribing. In this issue of JAMA Internal Medicine, 2 Research Letters examine the association between these payments and physician prescribing in diverse fields—biologic medications for inflammatory bowel diseases1 and gabapentinoids for various conditions, including seizure disorders and postherpetic neuralgia.2
Steinbrook R. Industry Payments and Physician Prescribing. JAMA Intern Med. 2019;179(10):1428–1429. doi:10.1001/jamainternmed.2019.1081
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.